Name:Yaacov Ben-David, Ph.D
Institutio：The Key Laboratory for Chemistry of Natural Products of GuizhouAnd Chinese Academy of Sciences(Guizhou Medical University).
Citizenship:Canadian/Israeli
Telephone:86-186-9072-4246
E-mail:yaacovbendavid@hotmail.com
ACADEMIC DEGREES
1978B.Sc, Biology, University of Teaching Training, Tehran, Iran
1982M.Sc, Molecular Virology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
1987Ph.D. Tumor biology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
1991Post doctorate fellow, Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto,Ontario, Canada
EMPLOYMENT HISTORY
1991- 1998 Assistant professor, Department of Medical Biophysics,University of Toronto
1991- 2006Scientist, Molecular and Cellular Biology, Sunnybrook ResearchInstitute, Toronto, Ontario, Canada
2006- 2012 Senior Scientist, Molecular and Cellular Biology, Sunnybrook Research Institute, Toronto, Ontario, Canada
1998- 2005 Associate professor, Department of Medical Biophysics, University of Toronto
2005- 2013 Professor, Department of Medical Biophysics,University of Toronto
2013-presentProfessor, Director of cancer biology platform, The state Key laboratory of Chemistry for Traditional Chinese Medicine of Guizhou and Chinese Academy of Sciences (Guizhou Medical University).
HONORS AND AWARDS
1982-1987Ph.D Fellowship, the Lautenberg Center for General and Tumor Immunology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
1987-1990Postdoctoral Fellowship, Leukemia Research Fund, Toronto, Ontario, Canada
1991-1992Career Research Scientist, Ontario Cancer Treatment and Research Foundation, Toronto,Ontario, Canada
1992-1998Career Scientist Credential, National Cancer Institute, Toronto, Ontario, Canada
1998-2006Career Research Scientist, Cancer Care Ontario, Toronto, Ontario, Canada
2006-Senior Research Scientist, Sunnybrook Research Institute, Toronto, Ontario, Canada
2007Murray Margarit Memorial Award, The Leukemia & Lymphoma Society of Canada
2016-Specially recruited foreign expert award of Guizhou province, China.
AWARDS COMPLETED OR IN PROGRESS (LAST 5 YEARS)
Agency:National Science Foundation of China(Regional)
Date of Award and Duration:2019-2022
Project Title:Research on the development of a novel histone deacetylase modifier for treatment of T-cell lymphoma
Total Amount of Award:410,000.00 RMB
Principal applicant:Dr. Yaacov Ben-David
Agency:National Science Foundation of China
Date of Award and Duration:2014-2018
Project Title:Identification and functional characterization of breast tumor susceptibility gene RGD1560402 in rat and human
Total Amount of Award:750,000.00 RMB
Principal applicant:Dr. Yaacov Ben-David
Agency:Guizhou Province Special Science and Technology project, No.[2013]6012).
Date of Award and Duration:2013-2016
Project Title:Identification of New Anti-tumor Drugs from Traditional Chinese Medicine for Treatment of Cancers Including Leukemia, Breast cancer and others
Total Amount of Award:2,000,000.00 RMB
Principal applicant:Dr. Yaacov Ben-David
Date of Award and Duration:2014-2017
Project Title:Genetic and environmental factors associated with the induction and progression of leukemia
Total Amount of Award:4,000,000.00 RMB
Principal applicant:Dr. Yaacov Ben-David
Agency:Canadian Institutes of Health Research
Date of Award and Duration:2011 to 2016
Project Title:Interaction of cancer initiating cells with the tumor microenvironment duringleukemogenesis
Total Amount of Award:$696,360
Principal applicant:Dr. Yaacov Ben-David(This grant was voluntarily terminated in 2013 following my laboratory relocation to Guiyang).
Agency:Canadian Breast Cancer Foundation
Date of Award and Duration:2011-2012
Project Title:Molecular basis of resistance to rat mammary carcinogenesis
Total Amount of Award:$148,145.00
Principal applicant:Dr. Michael ArcherCo-applicant:Dr. Yaacov Ben-David
PATENTS AND LICENSING AGREEMENTS
Title:Treatment, diagnosis and evaluation of anticancer therapy resistance in melanoma
Patent:Canada/U.S. Provisional Application Serial No. 6,573,050
Link:http://patents.justia.com/2003/06573050.html
Inventors:Yaacov Ben-David, B.J. Pak, R.S. Kerbel
Issued Date:June 03, 2003
Title:Development of monoclonal antibody against Fli-1
Licensing agreement:SantaCruze Biotechnology
Inventor:Yaacov Ben-David
Issue Date:March 2009
CHINESE PATENTS
1.双苄基异喹啉衍生物在制备用于治疗或预防肿瘤的药物中的用途, (Bi-Benzyl Isoquinoline Derivative, Preparation Method and Use Thereof in Hepatopathy Treatement and Prevention; Wedong Pan, Yaacov Ben-David et al; Patent No.201610396617.9).
2.柏花草胶囊的抗癌作用新用途(New function of the old drug of Xinyi company drug, Yaacov Ben-David and Heng Luo, applied).
3. 3-O-氯乙酰基-加加米宁及其制备方法和用途(Xiaojiang Hao, Yaacov Ben-David, Heng Luo, Liejun Huang. The preparation methods and application of 3‐O‐chloracetyl‐gagamine. Application No.:201610254158.8).
3-吲哚并[3,2-a]咔唑衍生物及其应用（LiuSheng,Yaacov Ben-David,XiaoXiao,XuMei. Indole and [3, 2 - a] carbazole derivatives &their applications. NO.CA105693729A.
PUBLICATIONS (Last 5 years)
1.Li, Y-J., Zhao XJ,Li, Y., Vecchiarelli-Federico LM., Datti A., Cheng, Y., andBen-David, Y.(2012).Drug-mediated inhibition of Fli-1 for the treatment of leukemia. Blood Cancer Journal,2, e54; Epub Jan 27.
2.Li, YJ., Vecchiarelli-Federico, LM., Li,Y-J.,Egan,SE., Spaner, D., Hough, MR.,andBen-David,Y.(2012)The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice.Blood, 119:4486-98.
3.Li, YJ, Liu,G., Li,Y., Vecchiarelli-Federico, LM., Liu,JC., Zacksenhaus,E., Shan,SW., Yang,BB., Dash, R., Fisher, PB., Archer, MC.,and Ben-David, Y (2013). mda-7/IL-24 Expression inhibits breast cancer through upregulation of growth arrest-specific gene 3 (gas3) and disruption of β1 integrin function. Mol Cancer Res. 11:593-603.
4.Tomic, J., McCaw, L., Li, Y., Hough, MR.,Ben-David, Y., Moffat, J., Spaner, DE. (2013). Resvertrol has anti-leukemic activity associated with decreased O-GLcHAcylated proteins. Exp. Hematol. 41:675-86.
5.Haeri, M., Li, Y., Li, Y., Li, Q., Spaner, DE.,Ben-David, Y. (2013). Insertional activation of myb by F-MuLV in SCID mice induces myeloid leukemia. Int J Oncol. 43: 169-76.
6.Xiao X. andBen-David Y. (2014). Erythropoietin. Encyclopedia of Immunotoxcity. DOI 10.1007/978-3-642-27786-3_466-2, Springer-Verlag Berlin Heidelberg.
7.Li, Y., Luo, H., Liu, T., Zachsenhaus, E., andBen-David, Y. (2015) The ets transcription factor Fli-1 in development, cancer and disease. Oncogene 35: 2022-031.
8.Li, Y., Shi, Y., McCaw, L., Li,YJ., Zhu, F., Gorczynski, R., Duncan, GS., Yang, B.,Ben-David, Yand Spaner, DE (2015) Micronvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. Blood 126:766-78.
9.Menezes, ME.,Shen, XN.,Das, SK.,Emdad, L.,Guo, C.,Yuan, F.,Li, YJ.,Archer, MC.,Zacksenhaus, E.,Windle, JJ.,Subler, MA.,Ben-David, Y.,Sarkar, D.,Wang, XY.,Fisher, PB(2015). MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer.Oncotarget.6:36928-42.
10.Li, YJ.,Liu, G.,Xia, L.,Xiao, X.,Liu, JC.,Menezes, ME.,Das, SK.,Emdad, L.,Sarkar, D.,Fisher, PB.,Archer, MC.,Zacksenhaus, E.,Ben-David, Y. (2015). Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice.Oncotarget.2015 6:36943-54.
11.Xia L, Plachynta M, Liu TJJ, Xiao X, Song JL, Li XG, Mu Z, Yao Y, Luo H, Hao XJ andBen-David Y.(2016). Pro-inflammatory effect of a TCM formula with strong anti-cancer activity in vitro impedes tumor inhibitory potential in vivo. Molecular and Clinical Oncology, 5, 717-23.
12.Lu C,Yan X,Tu Q,Di Y,Yuan C,Fang X,Ben-David Y,Xia L,Gong J,Shen Y,Yang Z,Hao X(2016). Isolation and Asymmetric Total Synthesis of Perforanoid A.Angew Chem Int Ed Engl.55:14373-77.
13.Dongsong T, Ping Y, Lei X, Yimin F, Wei G, Lie-Jun H,Ben-David Y, Xin X, Ying-tong D, Yuan, Chun-Mao Y, and Hao H-J (2016). Garmultins A-G, Biogenetically Related Polycyclic Acylphloroglucinols from Garcinia multiflora. Organic Letters, 18:5904-07.
14.Tan Y, Xiao X, Yao J, Han F, Lou H, Luo H, Liang G,Ben-David Y, Pan W (2016).Synthesis and Anti-cancer Activity of Glycosylated Derivatives of Diosgenin. Chemical Research in Chinese Universities. 33, 80–86.
15.Liu TJJ, Yao Y, Wang Y, Zhang G, Deng B, Jiang CY, Song JL, Li XG, Han F, Xiao X, Xia L, Li YJ, Plachynta M, Zhang M, Yan C, Mu SZ, Luo H, Zacksenhaus E, Hao XJ andBen-David Y.(2016). A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to megakaryocytic differentiation and suppress leukemogenesis. Oncotarget. 8:16728-43.
16.Zacksenhaus E, Liu JC, Jinag Zhe, Yao Y, Lei X, Shrestha M,Ben-David Y.(2017). Transcription factors in breast cancer-lesson from recent genomic analyses and therapeutic implications. Advanced in Protein Chemistry and structural Biology. 107:223-273.
17.Vecchiarelli-Federico LM, Liu TJJ, Yao Y, Gao Y, Li Y, Li Y-J,Ben-David Y.(2017). Fli-1 overexpression in erythroleukemic cells promotes erythroid de-differentiation while Spi-1/PU.1 exerts the opposite effect. International Journal of Oncology, 2:456-66.
18.Wang S, Liu JC, YoungJun Ju YJ, Voisin V, Wang D-W, Lehal R,Ben-David Y, Bader GD and Zacksenhaus E. (2017). MicroRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer JCI Insight: Aug 3;2(15).
19.Xia L, Xiao X, Liu W, Song Y, Liu TJJ, Li Y-J, Zacksenhaus E, Hao H-J,Ben-David Y(2018). Coactosin-like protein CLP/Cotl1 inhibits breast cancer through activation of IL-24/PERP pathway and suppression of non-canonical TGFβ signaling. Oncogene,doi:10.1038/onc.2017.342(IF 7.5)
20.Junjie Lan, Lan Huang, Huayong Lou, Chao Chen, Tangjingjun Liu, Shengcao Hu, Yao Yao, Junrong Song, Jun Luo, Yazhou Liu, Bin Xia,Lei Xia,Yaacov Ben-David*,Weidong Pan*(2018).Design, synthesis and biological evaluation of novel C14-urea-tetrandrine derivatives with potent anti-cancer activity. EJMC143:1968-1980.(IF 4.3)
21.WenM, ZhouB, Lin X, ChenY, LiuF, GouY, LiY,Ben-DavidY*,XiaoJiang Hao* (2017). Associations between XPD Lys751Gln polymorphism and leukemia: a meta-analysis.Front Genet, in press. (IF4.1)
22.Song J,Lan J,Chen C,Hu S,Song J,Liu W,Zeng X,Lou H,Ben-David Y,Pan W(2018). Design, synthesis and biological activity evaluation of novel C14-sulfonamide derivatives of tetrandrine as potential anticancer agents.MedChemComm, 9:1131-1141. (IF2.5)
23.Song Yu, Yao Yao, Xia Lei, Xiao Xiao, Liu Wuling, Yang Jue, Liu-Tang Jingjun, Song Jingrui, Song Jialei, Wang Ning, Liu Jielin*,Yaacov Ben-David*. (2018) Overexpression of TGM1 gene inhibits epithelial-mesenchymal transition in breast cancer cells. Tumor 38.
24.LiangSun, Miao He,Yaacov Ben-David, Ning Xu, Dahai Xu, Zhao-ying Yang,You-jun Li (2018). Mir193B regulation of RAN22A inhibits breast cancer growth and metastasis mediated by exosomes.International Journal of Oncology, in Press.
25.Jialei Song, Chunmao Yuan, Jue Yang, Tangjingjun Liu, Yao Yao, Xiao Xiao, Babu Gajendran, Dahai Xu, You-Jun Li, Chunlin Wang, Wuling Liu, Min Wen, David Spaner, Jorge Filmus, Eldad Zacksenhaus, Yiguo Zhang*, Xiaojiang Hao*andYaacov Ben-David*(2018).Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia.FEBS Journal, in press.
